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  Implication  for  health  policy/practice/research/medical 
education:
Delta Hepatitis treatment is a controversial issue. There are 
a few randomized, double blind, controlled studies on HDV 
treatment. Up to now, α-INF is the only confirmed medicine by 
FDA to heal HDV. This study is recommended to gastroenter-
ologists and infectious disease specialists to study this article.
  c 2011 Kowsar M.P.Co. All rights reserved.
Hepatitis D virus (HDV) infections remain a worldwide 
health problem. However, the clinical impact of these 
infections  is  often  underestimated,  and  therapeutic 
options for the infections are often unexploited. Gulsun 
et  al.  have  addressed  both  these  issues  in  the  paper 
“Treatment of chronic hepatitis D; a 9 years retrospective 
analysis” published in this issue of Hepatitis Monthly.
The present study was conducted in Diyarbakir, Eastern 
Turkey,  where  chronic  hepatitis  D  is  one  of  the  most 
prevalent liver diseases. HDV causes liver failure due to 
cirrhosis and hepatocellular carcinoma in a significant 
proportion of hepatitis B surface antigen (HBsAg) carriers. 
Over 8 years, The authors enrolled 46 patients with florid 
hepatitis D. These patients showed the typical features 
of HDV infections; most of them were young adult men 
with concomitant hepatitis B virus (HBV) infections that 
were positive for the antibody to hepatitis B antigen and 
not for the HBe antigen.
Treatment of hepatitis D is a formidable problem because 
HDV  totally  depends  on  the  replication  machinery  of 
the hepatocytes for its replication and has no specific 
transcriptases that can be targeted by antivirals. Efforts 
to target the concomitant HBV infection were in vain, 
and neither lamivudine nor adefovir could ameliorate 
hepatitis D or abrogate the underlying HBV infection. 
The authors used the only currently available therapeutic 
agent,  pegylated  interferon-alpha  (PEG-IFN-α),  for 
treating patients. The use of INFs for treating hepatitis D 
was introduced long back in 1980 after considering the 
efficacy of cytokines in treating hepatitis B. INF use is still 
based on the experiences from common practice rather 
than conclusive evidence from clinical trials, and many 
questions regarding the use of INFs in the management 
of HDV patients remain unanswered; some of these were 
answered in the study by Gulsun.
These authors determined whether long-term therapy 
is  more  efficacious  than  1-year  therapy.  Their  results 
showed  that  both  long-term  and  1-year  therapy  had 
the  same  outcomes;  this  finding  is  similar  to  that 
of  another  Turkish  study  (1).  Therefore,  if  there  is  no 
virologic response, then therapy should be discontinued 
after  a  year;  this  will  help  avoid  causing  unnecessary 
inconvenience to patients and reduce the costs incurred 
by health agencies.
Importantly,  in  this  study,  PEG-INF-α  treatment  was 
more  successful  than  in  most  previous  studies;  it 
achieved a sustained virologic response (SVR) rate of 41%. 
The good therapeutic outcome obtained with PEG-IFN-
α–2a in this study may be attributable to the relatively 
young age of the patients (median age, 35 years) because 
young age is correlated with less fibrosis, and in previous 
studies, fibrosis has been shown to reduce the efficacy Hepat Mon. 2011;11(9):701-702
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of IFN-α treatment. The age-specific analysis has indeed 
shown  that  the  decline  of  viremia  under  therapy  was 
more significant and the decrease of the Knodell score 
was higher in patients younger than 35 than in those 
older than 35, and in keeping with a better liver function 
in  less  advanced  disease,  side  effects  were  minor,  and 
only 5 patients required episodic reductions of therapy. 
Among the other studies that reported outcomes of PEG-
IFN treatment, a French study (2) included the highest 
proportion of non-cirrhotic patients with less advanced 
diseases  and  reported  the  highest  SVR  rate  (43%)  for 
patients treated with PEG-IFN-α–2b. Gulsun et al. reported 
a higher rate of relapse in patients who originally had 
elevated  serum  HDV-RNA  and  HBsAg  levels.  Further 
analysis  of  such  patients  in  terms  of  their  age,  initial 
symptoms and their response to 1-year and 2-year long 
therapy would be interesting.
Though  the  data  obtained  by  Gulsun  et  al.  are 
encouraging, the clinical significance of the SVR rates 
after IFN treatment achieved in this and other studies 
is  unclear.  Hepatitis  D  is  sustained  by  a  double  viral 
infection,  which  makes  the  evaluation  of  therapeutic 
endpoints more complex. The long-term significance of 
achieving virologic and clinical therapeutic targets other 
than absence of HBsAg has not been assessed so far. The 
viral titers during infections caused by HDV are much 
lower than those during infections caused by HBV and 
hepatitis C virus. The infectivity of HDV is very high and 
titers of the virus well below the detectability threshold of 
current assays might recapitulate cell to cell transmission 
of HDV within the liver and reactivate infection if the 
HBsAg is around. Thus, a long-term follow-up study of our 
patients is needed to clearly establish the therapeutic role 
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